ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0741

Prescribing Patterns of SGLT2 Inhibitors for Patients with Autoimmune Rheumatic Disease

Emily G Oakes1, Jack Ellrodt1, May Choi2, Hongshu Guan1 and Karen Costenbader1, 1Brigham and Women's Hospital, Boston, MA, 2Brigham and Women's Hospital | University of Calgary, Calgary, AB, Canada

Meeting: ACR Convergence 2022

Keywords: autoimmune diseases, Demographics, Heart disease, obesity

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 13, 2022

Title: Health Services Research Poster II

Session Type: Poster Session B

Session Time: 9:00AM-10:30AM

Background/Purpose: Sodium-glucose co-transporter 2 inhibitors (SGLT2i, dapagliflozin, canagliflozin, and empagliflozin) are a class of oral hypoglycemic medication for management of Type II diabetes mellitus (T2D), also demonstrated to lead to weight loss, decrease atherosclerotic cardiovascular risk, improve heart failure, reduce proteinuria, and prevent progression to end-stage renal disease (ESRD) in patients with chronic kidney disease. SGLT2i could have multiple benefits for patients with autoimmune rheumatic diseases (ARD), however these patients have not been included in clinical trials. Thus, we examined recent SGLT2i prescribing patterns for patients with ARD compared to patients without ARDs.

Methods: Using a centralized data registry from a large multihospital healthcare system we identified subjects with a ≥2 ICD-10 diagnostic codes for at least one of eight autoimmune rheumatic diseases prescribed dapagliflozin, canagliflozin, or empagliflozin between 1/1/2016 and 12/10/2021. Each ARD patient was matched by age, sex, and race to a control without ARD who was prescribed the same SGLT2i. Demographic and clinical data were collected on all subjects via data registry requests and electronic medical record review. Data comparison was conducted using Fisher exact tests and Chi-square analysis.

Results: We identified 488 total patients with ARD, including 265 rheumatoid arthritis, 97 psoriatic arthritis, 61 systemic lupus erythematosus, 34 Sjögren’s, 53 inflammatory myositis, 24 scleroderma, and 9 mixed connective tissue disease. 386 were prescribed empagliflozin, 54 dapagliflozin, and 48 canagliflozin. The majority (77.25%) of this ARD population had T2D. A large proportion had kidney disease (58.40%), obesity (36.48%), and heart failure (32.17%) at the time of SGLT2i prescription (Table 1.). When compared to matched controls without ARD, ARD patients had more obesity (p=0.003), CKD (p=< 0.001), and heart failure (p=0.09) (Table 2.).

Conclusion: To our knowledge, this is the first study to examine prescribing patterns of SGLT2i in individuals with systemic ARD, a population historically excluded from studies of this nature. These findings suggest that SGLT2i may be prescribed in cases of more serious illness in patients with ARD compared to patients without ARD. More research is needed to identify differences in outcomes between these two populations to justify these differences in prescribing patterns.

Supporting image 1

Supporting image 2


Disclosures: E. Oakes, None; J. Ellrodt, None; M. Choi, AstraZeneca, MitogenDx, mallinckrodt, Janssen, AbbVie/Abbott, Alimentiv, Amgen, AVIR Pharma Inc, BioJAMP, Bristol-Myers Squibb(BMS), Celltrion, Ferring, Fresenius Kabi, McKesson, Mylan, Takeda, Pendopharm, Pfizer, Roche; H. Guan, None; K. Costenbader, Eli Lilly, Janssen, Amgen, AstraZeneca Pharmaceuticals LP, GlaxoSmithKline(GSK), Gilead, Exagen, Neutrolis, Cel-Sci, Alkermes.

To cite this abstract in AMA style:

Oakes E, Ellrodt J, Choi M, Guan H, Costenbader K. Prescribing Patterns of SGLT2 Inhibitors for Patients with Autoimmune Rheumatic Disease [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/prescribing-patterns-of-sglt2-inhibitors-for-patients-with-autoimmune-rheumatic-disease/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/prescribing-patterns-of-sglt2-inhibitors-for-patients-with-autoimmune-rheumatic-disease/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology